Opendata, web and dolomites

MAMSCAN

New Method for Early Stage Breast Cancer Detection

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MAMSCAN project word cloud

Explore the words cloud of the MAMSCAN project. It provides you a very rough idea of what is the project "MAMSCAN" about.

gynecological    solution    france    groups    acquire    mammography    ing    images    detection    effect    launch    anatomic    fall    stage    invasive    finland    extensive    strategy    spain    doctor    age    economic    cancer    finalise    markets    acquisition    2016    planning    affordable    share    outside    commercialization    radiating    ipr    market    2026    competitors    device    pipeline    diagnostic    business    oy    screenings    30    ai    mortality    customers    acceptance    mu    preventive    fueled    population    patented    amiqo    price    involve    76    proprietary    worked    societal    82    lower    finnish    accuracy    uk    sales    pointing    day    speed    company    private    smei    neutral    enhanced    breast    imaging    clinics    services    women    significantly    considerable    ultrasound    50    diagnosis    frequency    health    clients    wavelength    initial    decreased    found    care    expensive    consists    million    examination    scanning    certification    treatment    pressure    clinical    attain    foreseen    annually    sweden    suspect    map    imaqen    direct    deadliest    first    2020    solutions    half    specialist    alternative    healthcare   

Project "MAMSCAN" data sheet

The following table provides information about the project.

Coordinator
IMAQEN OY 

Organization address
address: LIIKEHUONEISTO C JA D POHJOISRANTA 6 A
city: HELSINKI
postcode: 170
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Finland [FI]
 Project website http://www.imaqen.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2019-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IMAQEN OY FI (HELSINKI) coordinator 50˙000.00

Map

 Project objective

Imaqen Oy is a Finnish healthcare technology company developing an imaging solution for the early detection of breast cancer. Since 2016, we have worked on our proprietary technology, Amiqo that has the same diagnostic accuracy as the key competitors, mammography and breast ultrasound, while it is non-invasive and non-radiating. Amiqo consists of an imaging device using a patented μm-wavelength scanning, a proprietary frequency analysis enhanced by AI and an anatomic map pointing out the suspect areas for diagnosis carried out by a specialist doctor. Our initial target customers are private health care clinics who already have gynecological services. They are under pressure of finding affordable solutions for preventive healthcare fueled by women’s increasing awareness of the importance of early detection. The economic effect is considerable: the operating costs are significantly lower, it enables more images taken/day and its acquisition cost is neutral or lower. The end-clients are women under 50 or over 70 who fall outside the population level mammography screenings. 50% of breast cancer cases are found in these age groups annually. For women, Amiqo examination will be less than half the price of any current alternative. Through lower mortality and decreased treatment costs, Amiqo has a direct impact at societal level as breast cancer is the most common, the deadliest and the most expensive cancer for women in Europe. The next steps involve extensive clinical testing to finalise the product design, acquire certification and attain clinical acceptance. The SMEI funding will speed up the business planning in our priority markets, Finland, Sweden, France, the UK and Spain, including IPR pipeline, clinical acceptance strategy, user and technical requirements. The commercialization stage will be achieved by €1,76 million with the launch foreseen in 2020. The first goal is a 30% market share of the non-invasive imaging market by 2026 resulting in sales of €82 million.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MAMSCAN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MAMSCAN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

SmartDegrees (2020)

First anti-fraud plataform for the registration and certification of diplomas and academic certificates based in blockchain

Read More  

CAARESYS (2019)

CAARESYS: vehicle passenger monitoring system based on contactless low emission radio frequency radar.

Read More